Common sequence variants in pharmacodynamic and pharmacokinetic pathway-related genes conferring LDL cholesterol response to statins

Pharmacogenomics

Volumn 11, Issue 3, 2010, Pages 309-317

  Chien, Kuo Liong ^a   Wang, Kuei Chen ^a   Chen, Yen Ching ^a   Chao, Chia Lung ^a   Hsu, Hsiu Ching ^a   Chen, Ming Fong ^a   Chen, Wei J ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Candidate genes; Cholesterol; Low density lipoprotein; Statins

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; GENE PRODUCT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; PROTEIN ABCG8; PROTEIN HMGCR; PROTEIN SREBF1; ROSUVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHINESE; CONTROLLED STUDY; DRUG METABOLISM; FEMALE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHARMACODYNAMICS; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; ATP-BINDING CASSETTE TRANSPORTERS; BASE SEQUENCE; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; HAPLOTYPES; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TAIWAN;

EID: 77949575573     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.160     Document Type: Article

References (39)

1. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106, 3143-3421 (2002).
2. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 288, 2998-3007 (2002).
3. Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP Jr, Ridker PM: Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 291, 2821-2827 (2004).
4. Humphries SE, Hingorani A: Pharmacogenetics: progress, pitfalls and clinical potential for coronary heart disease. Vascul. Pharmacol. 44, 119-125 (2006).
5. Peters BJ, Klungel OH, de Boer A, Maitland-van der ZeeAH: Genetic determinants of response to statins. Expert Rev. Cardiovasc. Ther. 7, 977-983 (2009).
6. Ordovas JM, Mooser V: Nutrigenomics and nutrigenetics. Curr. Opin. Lipidol. 15, 101-108 (2004).
7. Shastry BS: Genetic diversity and new therapeutic concepts. J. Hum. Genet. 50, 321-328 (2005).
8. Kajinami K, Akao H, Polisecki E, Schaefer EJ: Pharmacogenomics of statin responsiveness. Am. J. Cardiol. 96, K65-K70; discussion K34-K35 (2005).
9. Mangravite LM, Thorn CF, Krauss RM: Clinical implications of pharmacogenomics of statin treatment. Am. J. Cardiol. 6, 360-374 (2006).
10. Schmitz G, Langmann T: Pharmacogenomics of cholesterol-lowering therapy Vascul. Pharmacol. 44, 75-89 (2006).
11. Thompson, JF Man M, Johnson KJ et al.: An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J. 5, 352-358 (2005).
12. Zineh I: Genetic polymorphisms and statin therapy. JAMA 292, 1302-1303 (2004).
13. Krauss RM, Mangravite LM, Smith JD et al.: Variation in the 3-hydroxyl-3-methylglutaryl coenzyme A reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. Circulation 117, 1537-1544 (2008).
14. International HapMap Consortium: A haplotype map of the human genome. Nature 437, 1299-1320 (2005).
15. Schmitz G, A Schmitz-Madry, Ugocsai P: Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapy. Curr. Opin. Lipidol. 18, 164-173 (2007).
16. Chien KL, Fang WH, Wen HC et al.: APOA1/C3/A5 haplotype and risk of hypertriglyceridemia in Taiwanese. Clin. Chim. Acta 390, 56-62 (2008).
17. Chien KL, Hsu HC, Su TC, Lee YT: Consistency in genetic inheritance mode and heritability patterns of triglyceride vs. high density lipoprotein cholesterol ratio in two Taiwanese family samples. BMC Genet. 4, 7-16 (2003).
18. Kao JT, Wen HC, Chien KL, Hsu HC, Lin SW: A novel genetic variant in the apolipoprotein A5 gene is associated with hypertriglyceridemia. Hum. Mol. Genet. 12, 2533-2539 (2003).
19. Mangravite LM, Krauss RM: Pharmacogenomics of statin response. Curr. Opin. Lipidol. 18, 409-414 (2007)
20. Kajinami K, Brousseau ME, Nartsupha C, Ordovas JM, Schaefer EJ: ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin. J. Lipid Res. 45, 653-656 (2004).
21. Salah D, Bohnet K, Gueguen R, Siest G, Visvikis S: Combined effects of lipoprotein lipase and apolipoprotein E polymorphisms on lipid and lipoprotein levels in the Stanislas cohort. J. Lipid Res. 38, 904-912 (1997).
22. Kivisto KT, Niemi M, Schaeffeler E et al.: Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics 14, 523-525 (2004).
23. Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ: CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia. Am. J. Cardiol. 93, 104-107 (2004).
24. Vermes A, Vermes I: Genetic polymorphisms in cytochrome P450 enzymes: effect on efficacy and tolerability of HMG-CoA reductase inhibitors. Am. J. Cardiovasc. Drugs 4, 247-255 (2004).
25. Chien KL, Hsu HC, Su TC, Chen MF, Lee YT, Hu FB: Apolipoprotein B and non-high-density lipoprotein cholesterol and risk of coronary heart disease in Chinese. J. Lipid Res. 48, 2499-2505 (2007).
26. Hommel G: A Comparison of two modified Bonferroni procedures. Biometrika 75, 383-386 (1988).
27. Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Statist. Soc. B 57, 289-300 (1995).
28. Zhao JH, Curtis D, Sham PC: Model-free analysis and permutation tests for allelic associations. Hum. Hered. 50, 133-139 (2000).
29. Tregouet DA, Escolano S, Tiret L, Mallet A, Golmard JL: A new algorithm for haplotype-based association analysis: the Stochastic-EM algorithm. Ann. Hum. Genet. 68, 165-177 (2004).
30. Lewontin RC: On measures of gametic disequilibrium. Genetics 120, 849-852 (1988).
31. Devlin B, Risch N: A comparison of linkage disequilibrium measures for fine-scale mapping. Genomics 29, 311-322 (1995).
32. Gauderman WJ: Sample size requirements for association studies of gene-gene interaction. Am. J. Epidemiol. 155, 478-484 (2002).
33. Salazar LA, Hirata MH, Quintao EC, Hirata RD: Lipid-lowering response of the HMG-CoA reductase inhibitor fuvastatin is infuenced by polymorphisms in the low-density lipoprotein receptor gene in Brazilian patients with primary hypercholesterolemia. J. Clin. Lab. Anal. 14, 125-131 (2000).
34. Burkhardt R, Kenny EE, Lowe JK et al.: Common SNPs in HMGCR in Micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon 13. Arterioscler. Thromb. Vasc. Biol. 28, 2078-2084 (2008).
35. Medina MW, Gao F, Ruan W, Rotter JI, Krauss RM: Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin. Circulation 118, 355-362 (2008).
36. Spence JT, KoudelkaAP, Tseng-Crank JC: Role of protein synthesis in the carbohydrate-induced changes in the activities of acetyl-CoA carboxylase and hydroxymethylglutaryl-CoA reductase in cultured rat hepatocytes. Biochem. J. 227, 939-947 (1985).
37. Fiegenbaum M, Silveira FR, van der Sand CR et al.: Determinants of variable response to simvastatin treatment: the role of common variants of SCAP, SREBF-1a and SREBF-2 genes. Pharmacogenomics J. 5, 359-364 (2005).
38. Wellcome Trust Case Control Consortium: Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447, 661-678 (2007).
39. Miltiadous G, Saougos V, Cariolou M, Elisaf MS: Plasma lipoprotein (a) levels and LDL-cholesterol lowering response to statin therapy in patients with heterozygous familial hypercholesterolemia. Ann. Clin. Lab. Sci. 36, 353-355 (2006).